This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Everyone can make an impact. Follow CRI social media channels to share cancer immunotherapy news and information with your friends and family.
Read real stories from others impacted by cancer and immunotherapy treatment, and connect with ImmunoAdvocates about their experiences.
CRI.ContactUs
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
In February 2017, Oswald became one of the first patients to receive pembrolizumab (Keytruda®) as first-line therapy for non-small cell lung cancer.
Dr. Kunle Odunsi discusses genomic testing, new treatments, and promising clinical trials in immunotherapy for ovarian cancer.